Mother of Southport victim praises ‘inspiring' blood donors
The mother of Southport attack victim Elsie Dot Stancombe has praised 'inspiring' blood donors during a drive in the seaside town.
Almost 100 people donated blood at the session at St John Stone Church in Southport on Saturday.
Seven-year-old Elsie was one of three girls murdered in the Southport mass stabbing attack at a Taylor Swift-themed dance class last summer.
Her parents, Jenni and Dave Stancombe, worked with NHS Blood and Transplant to organise the blood donation event through Elsie's Story, the charity they founded in her memory.
Among the NHS Blood and Transplant staff supporting the session were two members of the transport team based at the Liverpool blood centre who responded to the Southport attack.
Ms Stancombe said she wanted Elsie's Story to 'create a legacy of love and hope' in her daughter's name.
She added: 'Although the outcome for Elsie was tragically different, we know that blood transfusions were crucial for many of those injured that day.
'NHS Blood and Transplant made 10 emergency deliveries of blood to hospitals treating the casualties and that quick response meant the lifesaving blood was available for everyone who needed it.
'For some people here today, giving blood is their way of repaying those whose donations were so vital that day.'
Ms Stancombe added: 'We want Southport to be renowned for the warmth and generosity of its amazing community, not for the events of that day.
'Today has been a wonderful example of that.
'The atmosphere was so uplifting and inspiring and we are grateful to all the donors and staff for their support.'
Stephen Kuypers and Dave Oxton were among a team of drivers on shift the day of the Southport attacks who made 10 emergency blue-light deliveries of blood supplies in three hours to four hospitals, including Alder Hey Children's Hospital.
Blue lights are only used when a hospital requests blood products they urgently need for a specific patient or incident, NHS Blood and Transplant said.
If a patient's blood type is unknown, they can safely be given O negative blood, which makes it vital in emergencies.
Mr Kuypers said: 'On that dreadful day last July, I took the phone call from our hospital services team informing us of a major incident and instructing us to prepare for emergency deliveries.
'At the height of the response we were making three blue light deliveries an hour, which is extremely rare. I delivered two urgent orders to Alder Hey and Aintree hospitals.
'Hospital colleagues later told us that the quick response of the Liverpool transport team helped ensure that the patients received the best possible care.
'The was a very rewarding message to receive and it meant a lot to the team who all pulled together and put in extra hours that day to ensure all the deliveries were covered.'
NHS Blood and Transplant chief executive Dr Jo Farrar said: 'It is wonderful to see how many people have been inspired by Elsie's Story to give blood, and we are thankful to Elsie's brave parents Jenni and Dave for their incredible support.
'Because each donation can help up to three adults or six children, 300 lives or more will be saved and improved in Elsie's memory.
'A constant supply of blood is needed every day to help patients receiving treatment for conditions like cancer, sickle cell or giving birth as well as being prepared for unexpected emergencies and incidents, just like that dreadful day last July.'
NHS Blood and Transplant said it was appealing to blood and platelet donors across England to help fill tens of thousands of appointments at town and city donor centres over the coming days and weeks.
There are concerns that four bank holidays falling in six weeks could 'push blood supplies to critical levels' as donations often drop over bank holiday weekends.
The NHS is appealing for more O negative donations in particular, the blood type needed in emergencies.
NHS Blood and Transplant issued an amber alert in July 2024, which remains in place in England, due to a severe shortage of O negative blood triggered by the cyber-attack on London hospitals last year.
The attack meant major London hospitals could not cross match blood so the hospitals could only use O negative.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
London borough to completely ban junk food adverts amid obesity crisis
A London borough is set to ban adverts with promote "unhealthy" food in a bid to reduce levels of obesity and diabetes. Officers at Kingston Council in south-west London have drafted a report detailing the policy which will clamp down on notices of "harmful products" on all council-owned estates, assets and any advertising contracts If the scheme is approved, the council will be responsible for ensuring proposed adverts comply with the policy for all new contracts, as well as existing ones upon renewal. A joint strategic needs assessment carried out in the borough in 2023 found that instances of diabetes are on the rise, with 2,000 cases linked to obesity, the BBC reports. It further found that the top five risk factors for poor health and early deaths are tobacco, alcohol, high body mass index, poor diet and high systolic blood pressure. The report noted that the policy would "support strategic and operational plans to address the rising rates of obesity and chronic disease in the borough". Similar healthy advertising policies have been introduced by 24 local authorities across the UK, including nine London boroughs. Kingston Council's people committee will vote on whether to approve the policy on June 17.


Associated Press
3 hours ago
- Associated Press
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congressdescribe mechanistic insights for greater potency with verekitug compared to tezepelumab – – Supports potentially differentiated profile of verekitug across a broad range of inflammatory diseases, including severe asthma, chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP) – WALTHAM, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the presentation of translational pharmacology modeling data supporting verekitug's Thymic Stromal Lymphopoietin (TSLP) receptor targeting as a mechanism for greater potency when compared to treatments targeting the TSLP ligand. Data were presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress taking place June 13-16, 2025, in Glasgow, United Kingdom. TSLP is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective treatment approach. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases. Upstream is developing verekitug in multiple severe respiratory diseases including severe asthma, COPD, and CRSwNP. Verekitug is the only monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor. 'These data reinforce our belief in the differentiated profile of verekitug, as the model elucidates important biologic parameters that drive the differentiated rapid, substantial and sustained treatment effects observed through TSLP receptor inhibition with verekitug,' said Aaron Deykin, MD, Chief Medical Officer and Head of Research & Development of Upstream Bio. 'We look forward to further assessing the potential translation of this unique mechanism into clinical benefit in patients with severe respiratory diseases, first with top-line Phase 2 clinical data in CRSwNP in the third quarter of this year followed by data in severe asthma in the first half of 2026.' Data presented used an in silico system pharmacology modeling approach to provide a mechanism-based understanding for the observed potency of verekitug and are summarized as follows: A digital version of the presentation can be found on the Upstream Bio website. About TSLP and TSLPR Blockade Thymic Stromal Lymphopoietin (TSLP) is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective therapeutic strategy. TSLP activation is one of the first events in the inflammatory cascade stimulated by allergens, viruses and other triggers, initiating the activation of downstream targets such as IL-4, IL-5, IL-13, IL-17 and IgE. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor (TSLPR) presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases. About Verekitug Verekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to the TSLP receptor and inhibits proinflammatory signaling initiated by TSLP. It is the only monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor. Verekitug is currently being evaluated in two separate multi-national, placebo-controlled, randomized Phase 2 clinical trials, the VALIANT trial in patients with severe asthma (NCT06196879) and the VIBRANT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (NCT06164704). Upstream Bio is also initiating a Phase 2 clinical trial (NCT06981078) of verekitug in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In preclinical studies, verekitug demonstrated high occupancy of the TSLP receptor and potent inhibition of TSLP signaling. Additionally, verekitug inhibited cytokine production from both CD4+ T cells and ILC2 cells and completely suppressed skin allergic reactions in a non-human primate model, suggesting that it may be effective against multiple types of inflammation. Three clinical trials have been completed for verekitug, including a Phase 1 single-ascending dose (SAD) clinical trial and a Phase 1b multiple-ascending dose (MAD) clinical trial. In these trials, verekitug was well tolerated, had no clinically meaningful immunogenicity, and showed a predictable and consistent pharmacokinetic profile and high subcutaneous bioavailability. About Upstream Bio Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and is initiating development in chronic obstructive pulmonary disease. Upstream Bio's team is committed to maximizing verekitug's unique attributes to address the substantial unmet needs for patients underserved by today's standard of care. To learn more, please visit Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'continue,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'predict,' 'project,' 'seeks,' 'should,' 'target,' 'will' and variations of these words or similar expressions. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding: the clinical development of verekitug for the treatment of severe asthma, CRSwNP and COPD, including the initiation, timing, progress and results of ongoing and planned clinical trials; expectations for future discussions with regulatory authorities and the potential of the endpoints of the Company's clinical trials to produce data that could support submissions for product approval; expectations regarding the differentiation, safety, efficacy or tolerability of verekitug; expectations regarding the translation of pharmacology modeling data of verekitug to clinical effects; and assessments comparing non-head-to-head clinical data of verekitug to published data for tezepelumab. Any forward-looking statements in this press release are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to: Upstream Bio's ability to advance verekitug through clinical development, and to obtain regulatory approval of and ultimately commercialize verekitug on the expected timeline, if at all; the initiation, timing, progress and results of clinical trials; Upstream Bio's ability to fund its development activities and achieve development goals; Upstream Bio's dependence on third parties to conduct clinical trials and manufacture verekitug, and commercialize verekitug, if approved; Upstream Bio's ability to attract, hire and retain key personnel, and protect its intellectual property; Upstream Bio's financial condition and need for substantial additional funds in order to complete development activities and commercialize verekitug, if approved; regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; Upstream Bio's competitors and industry; and other risks and uncertainties described in greater detail under the caption 'Risk Factors' in Upstream Bio's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the SEC. Any forward-looking statements represent Upstream Bio's views only as of today and should not be relied upon as representing its views as of any subsequent date. Upstream Bio explicitly disclaims any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based except to the extent required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Investor and Media Contact: Meggan Buckwell Director, Corporate Communications and Investor Relations [email protected]
Yahoo
3 hours ago
- Yahoo
D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth
D-bal-max Glasgow, June 15, 2025 (GLOBE NEWSWIRE) --In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to supplements. D-Bal Max has emerged as a noteworthy option that claims to replicate the muscle-building benefits of anabolic steroids, but with a natural and safer approach. Understanding D-Bal Max's Formulation D-Bal Max's unique formula combines several scientifically researched ingredients aimed at supporting muscle synthesis and recovery without synthetic hormones or harmful chemicals. Pro BCAA Complex: Branched-chain amino acids (BCAAs) are essential amino acids that must be obtained through diet or supplements. Leucine, in particular, is known to activate the mTOR pathway—a key regulator of muscle protein synthesis. This means D-Bal Max supports the molecular processes that directly contribute to building new muscle tissue. 20-Hydroxyecdysterone: Sometimes called a 'plant steroid,' this compound naturally occurs in certain herbs and insects. Studies indicate it may increase muscle mass by stimulating protein synthesis and enhancing nitrogen retention, both vital for maintaining an anabolic (muscle-building) environment. Whey Protein Complex: Recognized for its high bioavailability, whey protein provides all nine essential amino acids. It supports muscle repair and growth by delivering rapid nourishment to fatigued muscles after workouts. How Does D-Bal Max Work? The supplement is designed to enhance: Protein Synthesis: This biological process builds new muscle fibers, repairing the microscopic damage caused during resistance training. ATP (Adenosine Triphosphate) Production: ATP is the energy currency in cells. Increasing ATP availability helps muscles sustain high-intensity exercise for longer periods. Serotonin Modulation: By reducing serotonin activity in muscles during exertion, D-Bal Max may delay fatigue onset, potentially improving endurance. Why Choose D-Bal Max Over Traditional Steroids? According to the official product website (https::// Traditional anabolic steroids like Dianabol have been associated with rapid muscle gain but also with significant health risks including liver toxicity, hormonal imbalances, cardiovascular strain, and psychological effects. These risks have led many users to seek safer alternatives. D-Bal Max provides a legal and natural substitute, avoiding synthetic hormones and minimizing adverse effects. Its ingredients have been selected based on scientific research that supports muscle growth without introducing foreign anabolic steroids into the body. Potential Benefits Supported by Research Muscle Mass Increase: Ingredients such as 20-Hydroxyecdysterone have been shown in clinical trials to promote lean muscle growth. Improved Recovery: BCAAs and whey protein help reduce muscle soreness and repair muscle fibers more efficiently. Enhanced Strength and Endurance: Through increased ATP production and delayed fatigue, users may experience better performance during workouts. Important Considerations for Users Individual Responses Vary: While many users report positive results, factors like genetics, training intensity, diet, and overall health can affect outcomes. Consultation Recommended: Before beginning any new supplement, it is advisable to consult with healthcare professionals, especially for those with medical conditions or who are taking other medications. Proper Training and Nutrition: Supplements like D-Bal Max are most effective when combined with a well-planned diet and consistent resistance training regimen. Market Position and Industry Trends The supplement industry is evolving with increasing demand for natural, science-backed products. D-Bal Max fits this trend by offering a steroid alternative that emphasizes safety and efficacy. As consumer awareness grows regarding the side effects of traditional steroids, natural supplements like D-Bal Max are gaining traction among athletes, bodybuilders, and fitness enthusiasts alike. Visit D-Bal Max Official Website To Read More.. Final Thoughts D-Bal Max is positioned as a credible, natural muscle-building supplement option that aligns with modern fitness goals centered on health and sustainability. While it may not produce results as rapidly as anabolic steroids, it offers a balanced approach with fewer risks. Ongoing research into its ingredients continues to support its potential benefits, but user diligence and professional guidance remain key to safe supplementation. Media Contact: Company name: D-Bal Max 12 Payne Street Glasgow G4 0LF United Kingdom 1 Chisholm Trail Road #450 US: +1 888-823-5131 (4am–6pm EST) UK: +44 20 4572 4051 (9am–11pm GMT) Email - support@ D-bal-max CONTACT: Media Contact: Company name: D-Bal Max 12 Payne Street Glasgow G4 0LF United Kingdom 1 Chisholm Trail Road #450 US: +1 888-823-5131 (4am–6pm EST) UK: +44 20 4572 4051 (9am–11pm GMT) Email - support@ in to access your portfolio